We found that higher FA pathway mutation burden correlated with sensitivity to volasertib: low concentration of volasertib (10 nmol/L) caused a ≥25% decrease in viability for 7/8 AML samples with ≥2 FA pathway mutations compared with only 3/8 of the AML samples with ≤1 FA pathway mutations (Fig. 4A and B). The gene discussed is FANCA; the disease is acute myeloid leukemia.